At 28-Days Does the Janssen Vaccine Prevent COVID?

The EUA Document Results Comparing Vaccinated with Non-Vaccinated Individuals

28 Days after the Injection there were fewer cases of COVID but The Difference was NO LONGER statistically significant. *p=NS*

Table 14. Vaccine Efficacy of First Occurrence of Moderate to Severe/Critical COVID-19 Including Non-centrally Confirmed Cases, With Onset at Least 14 or at Least 28 Days After Vaccination, by Baseline SARS-CoV-2 Status[a], Per Protocol Set

	Onset at Least 14 Days			Onset at Least 28 Days		
Baseline SARS-CoV-2 Serostatus[a]	Ad26.COV2.S Cases (N) Person-yrs	Placebo Cases (N) Person-yrs	VE% (95% CI)	Ad26.COV2.S Cases (N) Person-yrs	Placebo Cases (N) Person-yrs	VE%[b] (95% CI)
Regardless of baseline SARS-CoV-2 status	176 (21636) 3450.2	513 (21574) 3409.8	66.1% (59.7, 71.6)	114 (21424) 3436.3	326 (21199) 3385.9	65.5% (57.2, 72.4)
Positive	3 (2122) 336.3	4 (2030) 320.8	28.5% (-322.8, 89.5)	1 (2118) 336.1	2 (2021) 320.0	
Negative	173 (19514) 3113.9	509 (19544) 3089.1	66.3% (59.9, 71.8)	113 (19306) 3100.3	324 (19178) 3065.9	65.5% (57.2, 72.4)

Source: Sponsor tables GEFPE07A, GEFPE07C
N=Total number of participants at risk per category
[a] Based on serological test at baseline
[b] If fewer than 6 cases are observed for an endpoint then the VE is not shown





	Observed	Expected	Marginal Row Totals
Johnson & Johnson	21310 (21202.5) [0.55]	21094 (21201.5) [0.55]	42404
Nothing	20873 (20980.5) [0.55]	21087 (20979.5) [0.55]	41960
Marginal Column Totals	42183	42181	84364 (Grand Total)

The chi-square statistic is 2.1916. The *p*-value is .138761 *Not* significant at $p < .05$.

The chi-square statistic with Yates correction is 2.1713. The *p*-value is .140607. *Not* significant at $p < .05$.

Absolute Risk Reduction (ARR) = 1.54% minus 0.53% = 1.01%